- Home
- CMND vs MYNZ Comparison
CMND vs MYNZ Comparison
Compare CMND & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMND
- MYNZ
- Stock Information
- Founded
- CMND 2017
- MYNZ 2021
- Country
- CMND Canada
- MYNZ Germany
- Employees
- CMND N/A
- MYNZ N/A
- Industry
- CMND Biotechnology: Pharmaceutical Preparations
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CMND Health Care
- MYNZ Health Care
- Exchange
- CMND Nasdaq
- MYNZ Nasdaq
- Market Cap
- CMND 4.8M
- MYNZ 5.5M
- IPO Year
- CMND N/A
- MYNZ 2021
- Fundamental
- Price
- CMND $0.85
- MYNZ $1.37
- Analyst Decision
- CMND
- MYNZ Buy
- Analyst Count
- CMND 0
- MYNZ 2
- Target Price
- CMND N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CMND 122.4K
- MYNZ 118.7K
- Earning Date
- CMND 06-12-2025
- MYNZ 07-07-2025
- Dividend Yield
- CMND N/A
- MYNZ N/A
- EPS Growth
- CMND N/A
- MYNZ N/A
- EPS
- CMND N/A
- MYNZ N/A
- Revenue
- CMND N/A
- MYNZ $893,991.00
- Revenue This Year
- CMND N/A
- MYNZ $26.06
- Revenue Next Year
- CMND N/A
- MYNZ $4.97
- P/E Ratio
- CMND N/A
- MYNZ N/A
- Revenue Growth
- CMND N/A
- MYNZ N/A
- 52 Week Low
- CMND $0.80
- MYNZ $1.34
- 52 Week High
- CMND $2.30
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- CMND 41.60
- MYNZ 23.25
- Support Level
- CMND $0.83
- MYNZ $1.34
- Resistance Level
- CMND $0.93
- MYNZ $1.48
- Average True Range (ATR)
- CMND 0.06
- MYNZ 0.13
- MACD
- CMND 0.00
- MYNZ -0.01
- Stochastic Oscillator
- CMND 32.64
- MYNZ 3.72
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.